Tag Archives: Raju Prasad
William Blair Thinks Global Blood Therapeutics’ Stock is Going to Recover
William Blair analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) today. The company’s shares closed last Monday at $41.35, close to its 52-week low of $36.49. According to TipRanks.com, Prasad is a 5-star
William Blair Believes Crispr Therapeutics AG (NASDAQ: CRSP) Won’t Stop Here
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The company’s shares closed last Friday at $147.54, close to its 52-week high of $151.11. According to TipRanks.com,
William Blair Keeps Their Buy Rating on Poseida Therapeutics (PSTX)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Poseida Therapeutics (PSTX – Research Report). The company’s shares closed last Friday at $10.68. According to TipRanks.com, Prasad is a 5-star analyst with an average
William Blair Sticks to Their Buy Rating for Cellectis SA (CLLS)
William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS – Research Report) today. The company’s shares closed last Tuesday at $19.70. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 16.4% and
Alexion Pharmaceuticals (ALXN) Receives a Hold from William Blair
In a report released today, Raju Prasad from William Blair maintained a Hold rating on Alexion Pharmaceuticals (ALXN – Research Report). The company’s shares closed last Tuesday at $116.08. According to TipRanks.com, Prasad is a 5-star analyst with an average
Selecta Biosciences (SELB) was Downgraded to a Hold Rating at William Blair
William Blair analyst Raju Prasad downgraded Selecta Biosciences (SELB – Research Report) to Hold today. The company’s shares closed last Wednesday at $2.48. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.6% and a 53.5%
